These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6089696)

  • 1. Separation of small-cell from non-small-cell lung cancer. The Southeastern Cancer Study Group pathologists' experience.
    Vollmer RT; Ogden L; Crissman JD
    Arch Pathol Lab Med; 1984 Oct; 108(10):792-4. PubMed ID: 6089696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study.
    Stang A; Pohlabeln H; Müller KM; Jahn I; Giersiepen K; Jöckel KH
    Lung Cancer; 2006 Apr; 52(1):29-36. PubMed ID: 16476504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small cell carcinoma versus other lung malignancies: diagnosis by fine-needle aspiration cytology.
    Delgado PI; Jorda M; Ganjei-Azar P
    Cancer; 2000 Oct; 90(5):279-85. PubMed ID: 11038424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibodies distinguishing human small cell lung cancer from non-small cell lung cancer].
    Ge XR; Wang J; Che YF; Tong CA; Shu LZ; Zhang TM; Lo JM
    Shi Yan Sheng Wu Xue Bao; 1988 Jun; 21(2):251-5. PubMed ID: 2849270
    [No Abstract]   [Full Text] [Related]  

  • 5. Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
    Rossi G; Cavazza A; Marchioni A; Migaldi M; Bavieri M; Facciolongo N; Petruzzelli S; Longo L; Tamberi S; Crinò L
    Mod Pathol; 2003 Oct; 16(10):1041-7. PubMed ID: 14559988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
    Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reported management of lung cancer in Victoria in 1993: comparison with best practice. Anti-Cancer Council of Victoria Lung Cancer Study Group.
    Richardson GE; Thursfield VJ; Giles GG
    Med J Aust; 2000 Apr; 172(7):321-4. PubMed ID: 10844918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?
    Colby TV; Tazelaar HD; Travis WD; Bergstralh EJ; Jett JR
    Cancer; 2002 Dec; 95(11):2361-5. PubMed ID: 12436443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Brain metastases of bronchial and breast carcinoma. Differences in metastatic behavior and prognosis].
    Nieder C; Niewald M; Hagen T
    Radiologe; 1995 Nov; 35(11):816-21. PubMed ID: 8657883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Young RH
    Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential diagnosis of small cell neuroendocrine carcinoma of the lung.
    Warren WH; Gould VE
    Chest Surg Clin N Am; 1997 Feb; 7(1):49-63. PubMed ID: 9001755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frozen section diagnoses of small pulmonary nodules: accuracy and clinical implications.
    Marchevsky AM; Changsri C; Gupta I; Fuller C; Houck W; McKenna RJ
    Ann Thorac Surg; 2004 Nov; 78(5):1755-9. PubMed ID: 15511468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
    Oremek GM; Sapoutzis N
    Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
    Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
    Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma.
    Perez EA; Loprinzi CL; Sloan JA; Owens DT; Novotny PJ; Bonner JA
    Cancer; 1997 Aug; 80(4):676-80. PubMed ID: 9264350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.